Development of Targeted Alpha Particle Therapy for Solid Tumors

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmaceutical Chemistry

Background:

• Targeted alpha-particle therapy (TAT) utilizes alpha-emitting radionuclides for cancer treatment.
• Alpha particles offer high linear energy transfer (LET) and short tissue range, maximizing tumor cell damage while sparing healthy tissues.
• Recent clinical trials show promising efficacy of TAT for metastatic castration-resistant prostate cancer.

Purpose of the Study:

• To provide a comprehensive review of targeted alpha-particle therapy.
• To discuss key aspects including radionuclide properties, therapeutic mechanisms, targeting strategies, dosimetry, and optimization.
• To summarize preclinical and clinical applications of TAT.

Main Methods:

• Review of current literature on alpha-particle-emitting radionuclides and their clinical relevance.
• Analysis of TAT mechanisms, targeting moieties, and radiometal chelators.
• Discussion of radiation dosimetry calculations and medicinal chemistry approaches for lead optimization.
• Summary of preclinical and clinical study outcomes.

Main Results:

• TAT demonstrates significant potential due to the cytotoxic payload of alpha particles and targeted delivery systems.
• Various radionuclides, targeting moieties, and chelators are available for TAT development.
• Accurate dosimetry and medicinal chemistry are crucial for optimizing TAT efficacy and safety.
• TAT has shown remarkable efficacy in treating metastatic castration-resistant prostate cancer.

Conclusions:

• Targeted alpha-particle therapy is a highly effective cancer treatment modality, particularly for advanced prostate cancer.
• Continued research in radionuclide selection, targeting strategies, and optimization is essential for advancing TAT.
• TAT represents a promising frontier in precision oncology, minimizing off-target toxicity.